Vitamin D₃supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial.

ABSTRACT:

Objectives

Since vitamin D insufficiency is common worldwide in people with HIV, we explored safety and efficacy of high dose cholecalciferol (D₃) in Botswana, and evaluated potential modifiers of serum 25 hydroxy vitamin D change (Δ25D).

Design

Prospective randomized double-blind 12-week pilot trial of subjects ages 5.0-50.9 years.

Methods

Sixty subjects randomized within five age groups to either 4000 or 7000 IU per day of D₃ and evaluated for vitamin D, parathyroid hormone, HIV, safety and growth status. Efficacy was defined as serum 25 hydroxy vitamin D (25D) ≥32 ng/mL, and safety as no simultaneous elevation of serum calcium and 25D. Also assessed were HIV plasma viral RNA viral load (VL), CD4%, anti-retroviral therapy (ART) regime, and height-adjusted (HAZ), wei

SUBMITTER: Steenhoff AP 

PROVIDER: S-EPMC4338235 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature